Sarcoma  >>  Cotellic (cobimetinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cotellic (cobimetinib) / Exelixis, Roche
NCT02768207 / 2015-001731-20: A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma

Completed
2
40
Europe
Cobimetinib, GDC-0973, RO5514041, XL518, Vemurafenib, RO5185426
Hoffmann-La Roche
Metastatic Melanoma
12/17
06/19
2018-004623-36: MEGALiT - a study in which the effect of established cancer drugs is investigated on new cancers that have a specific molecular signature MEGALiT - en studie där effekten av etablerade cancerläkemedel undersöks på nya cancersjukdomar som har en specifik molekylär signatur

Not yet recruiting
2
154
Europe
Tecentriq, Cotellic, Zejula, Everolimus, RO5514041/F04, Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Tablet, Tecentriq, Cotellic, Zejula
Uppsala University Hospital, Roche AB
In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy, In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy, Diseases [C] - Cancer [C04]
 
 
NACHO COBI, NCT04079179: Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Recruiting
2
90
US
Cobimetinib, COTELLIC, RO5514041
Carl Allen, Baylor College of Medicine, North American Consortium for Histiocytosis, Genentech, Inc.
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
12/24
12/29
2019-000987-80: A multicentre trial evaluating the combination of a MEK inhibitor and a PDL1 inhibitor in pediatric and adult patients with locally advanced and/or metastatic soft tissue sarcoma Etude multicentrique, menée en ouvert, de Phase I/II visant à évaluer la combinaison d’un inhibiteur de MEK et d’un anti-PDL1 chez des patients pédiatriques et adultes présentant un sarcome des tissus mous de stade avancé ou métastatique

Not yet recruiting
1/2
80
Europe
atezolizumab, cobimetinib, R05541267, R05514041, RO5514041/F12, Concentrate for solution for infusion, Film-coated tablet, Powder for oral solution, TECENTRIQ, COTELLIC
Centre Léon Bérard, INCA
advanced/metastatic soft tissu sarcoma sarcomes des tissus mous de stade avancé/métastatique, soft tissu sarcoma sarcomes des tissus mous, Diseases [C] - Cancer [C04]
 
 
COTESARC, NCT04216953: MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma

Recruiting
1/2
320
Europe
Cobimetinib, GDC-0973, Atezolizumab, RO5541267
Centre Leon Berard
Sarcoma,Soft Tissue
02/26
02/27

Download Options